Lyell Immunopharma (NASDAQ:LYEL) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Lyell Immunopharma (NASDAQ:LYEL) from a hold rating to a sell rating in a report issued on Saturday,Wall Street Zen reports.

Several other brokerages have also recently weighed in on LYEL. Citizens Jmp reaffirmed a “market outperform” rating and issued a $34.00 price target on shares of Lyell Immunopharma in a research report on Monday, June 15th. Stifel Nicolaus initiated coverage on Lyell Immunopharma in a report on Thursday, August 6th. They set a “buy” rating and a $36.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Friday, July 17th. Zacks Research upgraded Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Finally, Royal Bank Of Canada set a $34.00 target price on Lyell Immunopharma in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.86.

Lyell Immunopharma Trading Down 5.3%

Shares of LYEL stock opened at $11.33 on Friday. The firm has a fifty day simple moving average of $13.99 and a two-hundred day simple moving average of $17.15. Lyell Immunopharma has a 12 month low of $11.24 and a 12 month high of $45.00. The firm has a market capitalization of $277.58 million, a PE ratio of -0.88 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. On average, equities analysts predict that Lyell Immunopharma will post -7.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Opaleye Management Inc. increased its position in shares of Lyell Immunopharma by 334.9% during the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after acquiring an additional 264,928 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in Lyell Immunopharma by 119.4% during the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock worth $595,000 after acquiring an additional 23,028 shares during the period. Velan Capital Investment Management LP boosted its position in Lyell Immunopharma by 2.9% in the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock worth $1,475,000 after purchasing an additional 3,000 shares during the last quarter. venBio Partners LLC purchased a new position in Lyell Immunopharma in the second quarter worth $4,744,643. Finally, Bank of New York Mellon Corp bought a new position in Lyell Immunopharma in the 2nd quarter valued at $347,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for patients with cancer. The company’s research is aimed at addressing challenges that can limit the effectiveness of cellular immunotherapies, including T-cell exhaustion, inadequate persistence and difficulty penetrating solid tumors.

Lyell uses its cellular reprogramming and genetic engineering technologies to develop therapeutic T cells, including chimeric antigen receptor (CAR) T-cell candidates.